Aberrant EGFR and chromosome 7 associate with outcome in laryngeal cancer

Laryngoscope

Volumn 115, Issue 7, 2005, Pages 1212-1218

  Morrison, Larry E ^a   Jacobson, Kristine K ^a   Friedman, Michael ^b   Schroeder, James W ^b   Coon, John S ^b  

^a ABBOTT LABORATORIES   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; PARAFFIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CHROMOSOME 7; CHROMOSOME ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENES, ERBB-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 21844460791     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MLG.0000163755.21035.8F     Document Type: Article

References (12)

1. Le QT, Giaccia AJ. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res 2003;9:4287-4295.
2. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-S8.
3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9-S15.
4. Wen QH, Miwa T, Yoshizaki T, et al. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884-888.
5. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-3664.
6. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
7. Venkatesan TK, Kuropkat C, Caldarelli DD, et al. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 1999;109: 1329-1333.
8. Kearsley JH, Bryson G, Battistutta D, et al. Prognostic importance of cellular DNA content in head-and-neck squamous-cell cancers. A comparison of retrospective and prospective series. Int J Cancer 1991;47:31-37.
9. Rasnick D, Duesberg PH. How aneuploidy affects metabolic control and causes cancer. Biochem J 1999;340(Pt 3): 621-630.
10. Duesberg P, Rasnick D. Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil Cytoskeleton 2000;47:81-107.
11. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
12. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-1067.